for subscribers

Aspen CEO says deal making to resume in emerging markets

Share your Subscriber Article
You have 5 articles to share every month. Send this story to a friend!
(Supplied)
(Supplied)

Johannesburg - Aspen [JSE:APN] sees further acquisitions in the next 12 months as strong revenue and lower capital expenditure restore its firepower after the purchase of two anesthetics portfolios last year.

The potential deals will probably be made in the South African company’s existing pharmaceutical markets, with womens’ health a possible area of expansion, chief executive officer Stephen Saad, 53, said in an interview at Aspen’s headquarters in Durban on Friday.

The drug maker, which has operations in more than 150 countries, will focus on emerging rather than developed markets, the billionaire said.

There’s more to this story
Subscribe to News24 and get access to our exclusive journalism and features today.
Subscribe
Already a subscriber? Sign in
ZAR/USD
16.70
(+0.32)
ZAR/GBP
21.27
(+1.10)
ZAR/EUR
19.56
(+0.88)
ZAR/AUD
11.99
(+1.12)
ZAR/JPY
0.16
(+0.70)
Gold
1904.00
(-0.66)
Silver
24.36
(-2.50)
Platinum
872.04
(-1.42)
Brent Crude
42.14
(-3.94)
Palladium
2246.50
(-1.73)
All Share
53199.45
(-0.22)
Top 40
49064.23
(-0.18)
Financial 15
9555.17
(+0.37)
Industrial 25
71830.55
(+1.15)
Resource 10
52856.15
(-1.99)
All JSE data delayed by at least 15 minutes morningstar logo
Company Snapshot
Voting Booth
Do you think it was a good idea for the government to approach the IMF for a $4.3 billion loan to fight Covid-19?
Please select an option Oops! Something went wrong, please try again later.
Results
Yes. We need the money.
11% - 1333 votes
It depends on how the funds are used.
73% - 8730 votes
No. We should have gotten the loan elsewhere.
16% - 1924 votes
Vote